Schedule 13G ownership disclosure
Stoke Therapeutics Inc
Security class unavailable · CUSIP: 86150R107
Event date: 2024-09-30
Legacy cover-page extraction is best effort and may not include every reporting person.
- Filing-level shares
- 5,187,191
- Percent of class
- 9.9000%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000902664-24-006512
- Form type
- SC 13G
- Filer
- Lynx1 Capital Management LP
- CIK
- CIK 1910456
- Filed
- Nov 14, 2024
- Reporting period
- Sep 30, 2024
- Description
- Schedule 13G beneficial ownership